NPM1 and acute myeloid leukemia: Notably, a subset of NPM1-mutated AML patients from TCGA and GEO databases did not appear high FTO expression compared with NPM1-unmutated AML patients, which might be as a result of the regulation of FTO expression by multiple factors such as estrogen, total fatty acid intake in diet, and arsenic exposure, and so on and the highly heterogeneity of AML (41–43).